Genmab A/S (NASDAQ:GMAB) Given Average Recommendation of “Moderate Buy” by Brokerages

Genmab A/S (NASDAQ:GMAB) has been assigned an average rating of “Moderate Buy” from the thirteen research firms that are presently covering the stock, Marketbeat reports. Four equities research analysts have rated the stock with a hold recommendation, eight have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $41.33.

GMAB has been the topic of a number of research analyst reports. Leerink Partners upgraded shares of Genmab A/S from a “market perform” rating to an “outperform” rating and set a $27.00 target price on the stock in a research note on Thursday, February 13th. BNP Paribas upgraded shares of Genmab A/S from a “strong sell” rating to a “hold” rating in a research note on Tuesday, February 11th. William Blair upgraded shares of Genmab A/S from a “market perform” rating to an “outperform” rating in a research note on Tuesday. HC Wainwright reiterated a “buy” rating and issued a $50.00 target price on shares of Genmab A/S in a research note on Thursday, January 23rd. Finally, Truist Financial lowered their target price on shares of Genmab A/S from $50.00 to $45.00 and set a “buy” rating on the stock in a research note on Tuesday.

Genmab A/S Stock Down 7.8 %

Shares of GMAB opened at $20.26 on Wednesday. The company’s fifty day moving average is $21.29 and its 200-day moving average is $22.54. Genmab A/S has a 12 month low of $18.64 and a 12 month high of $31.88. The firm has a market cap of $13.41 billion, a price-to-earnings ratio of 11.64, a price-to-earnings-growth ratio of 2.65 and a beta of 0.98.

Genmab A/S (NASDAQ:GMAB) last announced its quarterly earnings results on Wednesday, February 12th. The company reported $0.57 EPS for the quarter, topping the consensus estimate of $0.28 by $0.29. Genmab A/S had a net margin of 36.30% and a return on equity of 16.78%. As a group, research analysts predict that Genmab A/S will post 1.45 earnings per share for the current fiscal year.

Institutional Trading of Genmab A/S

A number of hedge funds have recently bought and sold shares of the stock. China Universal Asset Management Co. Ltd. boosted its holdings in Genmab A/S by 10.3% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 8,891 shares of the company’s stock valued at $186,000 after purchasing an additional 827 shares during the period. EverSource Wealth Advisors LLC lifted its holdings in shares of Genmab A/S by 295.3% during the 4th quarter. EverSource Wealth Advisors LLC now owns 1,257 shares of the company’s stock worth $26,000 after acquiring an additional 939 shares during the period. Lindbrook Capital LLC lifted its holdings in shares of Genmab A/S by 105.4% during the 4th quarter. Lindbrook Capital LLC now owns 1,851 shares of the company’s stock worth $39,000 after acquiring an additional 950 shares during the period. GAMMA Investing LLC lifted its holdings in shares of Genmab A/S by 96.6% during the 4th quarter. GAMMA Investing LLC now owns 2,139 shares of the company’s stock worth $45,000 after acquiring an additional 1,051 shares during the period. Finally, Eagle Asset Management Inc. lifted its holdings in shares of Genmab A/S by 10.0% during the 3rd quarter. Eagle Asset Management Inc. now owns 12,356 shares of the company’s stock worth $285,000 after acquiring an additional 1,121 shares during the period. 7.07% of the stock is owned by institutional investors.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.